Nevada Jury Finds Actos Not Defective, Warning Adequate In 3rd Bladder Cancer Trial

Nevada Jury Finds Actos Not Defective, Warning Adequate In 3rd Bladder Cancer Trial

LAS VEGAS - A Nevada state court jury on Dec. 16 found that Takeda Pharmaceuticals Co. Ltd. did not defectively design its Actos diabetes drug or fail to warn a plaintiff about the risk of bladder cancer (Allen K. Alsabagh v. Takeda Pharmaceuticals America, Inc., et al., No. A-12-665708-C, Nev. Dist., Clark Co.).

Find full version on lexis Advance®
Access this news story on lexis.com®